RA Capital Management L.P. Sells 5,483,166 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)

RA Capital Management L.P. lowered its stake in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 87.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 766,834 shares of the biopharmaceutical company's stock after selling 5,483,166 shares during the period. RA Capital Management L.P. owned 1.17% of Regulus Therapeutics worth $1,204,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. NEA Management Company LLC purchased a new stake in shares of Regulus Therapeutics in the third quarter worth about $10,154,000. Vanguard Group Inc. boosted its holdings in Regulus Therapeutics by 158.4% in the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company's stock valued at $2,132,000 after purchasing an additional 453,784 shares during the period. Victory Capital Management Inc. grew its position in shares of Regulus Therapeutics by 10.4% during the 3rd quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company's stock valued at $626,000 after purchasing an additional 37,480 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company's stock valued at $211,000 after purchasing an additional 42,600 shares in the last quarter. Finally, Creative Planning bought a new position in shares of Regulus Therapeutics in the third quarter worth $26,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on RGLS shares. StockNews.com upgraded Regulus Therapeutics to a "sell" rating in a research report on Tuesday, September 17th. Oppenheimer reissued an "outperform" rating and issued a $7.00 price target on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. Finally, HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $10.80.

Regulus Therapeutics Trading Down 5.9 %

Shares of RGLS traded down $0.10 during mid-day trading on Thursday, reaching $1.52. The company's stock had a trading volume of 96,703 shares, compared to its average volume of 1,194,455. Regulus Therapeutics Inc. has a 52 week low of $1.08 and a 52 week high of $3.79. The stock has a market cap of $99.23 million, a PE ratio of -1.50 and a beta of 1.61. The company's fifty day moving average price is $1.53 and its two-hundred day moving average price is $1.73.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.